ClinicalTrials.gg
CompletedNCT01202227Updated Jan 28, 2021Results posted

An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain

A Phase 3 interventional study of pregabalin in Spinal Cord Diseases, Spinal Cord Injuries and Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 26 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Primary conditionSpinal Cord InjuriesRegistry: Spinal Cord DiseasesReclassifiedWhy we changed it
Registry
Spinal Cord Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Spinal Cord Injuries
Why
  1. The study's listed conditions name Spinal Cord Injuries, a narrower term within Spinal Cord Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).

02

Conditions studied

  • Spinal Cord Diseases
  • Spinal Cord Injuries
  • Neuralgia
  • Pain

Keywords

  • Central Nervous System Diseases
  • Therapeutic Uses
  • Wounds and Injuries
  • Trauma
  • Nervous System
  • pregabalin
03

In context

Spinal Cord Injuries Reclassified

2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

This study's enrollment of 104 is above the median of 24 across 1,635 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Compared within Spinal Cord Injuries, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Spinal Cord Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria for subjects to be shifted from Study A0081107

  • Subjects who completed the 18-week study period in Study A0081107 conducted for chronic neuropathic pain after spinal cord injury;
  • Subjects who completed assessments of all efficacy endpoints until the end of the treatment phase of the preceding Study A0081107 (V7);

Inclusion criteria for subjects to be new participants in this study

  • Subjects with central neuropathic pain after stroke or multiple sclerosis;
  • At least 6 months have passed after the onset of central neuropathic pain;
  • Pain VAS at least 40mm in Visit 1 and Visit 2;

Exclusion criteria

Exclusion Criteria:

  • \< 60 mL/min;
  • count \< 100 × 103/mm3 ; White blood cell (WBC) count \< 2500 / mm3; \< 1500/ mm3;
  • Subjects who are expected to require surgery during the trial;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period

    Drug: pregabalin

Interventions

  • Pregabalin capsules taken twice a daily (150-600mg/day)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Peripheral Edema

    Number of participants who had peripheral edema in lower extremities. Edema was categorized as follows: trace, pitting 1 (lower leg), 2 (lower leg to knee), and 3 (above knee and /or presacral edema).

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  2. Number of Participants With Facial/Periorbital Edema

    Number of participants who had facial or periorbital edema.

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  3. Number of Participants With Generalized or Abdominal Edema

    Number of participants who had generalized or abdominal edema.

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  4. Number of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT)

    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  5. Number of Participants With Localized Tenderness Related to Deep Vein Thrombosis (DVT)

    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  6. Number of Participants With Swelling Related to Deep Vein Thrombosis (DVT)

    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  7. Number of Participants With Pitting Edema Related to Deep Vein Thrombosis (DVT)

    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  8. Number of Participants With Collateral Superficial Veins (Non-varicose) Related to Deep Vein Thrombosis (DVT)

    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  9. Number of Participants With Skin Redness Related to Deep Vein Thrombosis (DVT)

    DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

    Time frame: Baseline, Weeks 4, 20, 36, 52, and 53

  10. Number of Participants With Visual Field Deteriorated

    Number of participants who had normal visual field at baseline and showed abnormal result after the study treatment, assessed by confrontational visual field test (neurological examination).

    Time frame: 53 weeks

  11. Number of Participants With Deterioration in Neurological Examination Findings

    Worsening of the condition relative to baseline was reported as deteriorated. Assessment categories are as follows: normal or abnormal for Cranial Nerve Function, Mental State, and Coordination; normal, mild, moderate, or severe ataxia for Gait; none/absent, normal, or hyper-reflexic for Deep Tendon Reflexes; absent or present for Abnormal Reflexes; normal, mild, moderate, or severe weakness for Muscle Strength; slight, more marked, or considerable increase, or affected parts rigid in flexion or extension for Muscle Tone; absent or present for Sensory Function.

    Time frame: 53 weeks

  12. Number of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS)

    The Sheehan-STS is an 8-item prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Participants who reported a score of ≥1 (5-point scale ranging from 0: not at all to 4: extremely) for Item 2, 3, 4 or 5 of the Sheehan-STS prognostic scale is considered to have suicidal ideation as the scores are mapped to Category 4 (suicide ideation) of the Columbia Classification Algorithm of Suicide Assessment.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52

Secondary outcomes

  1. Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Total Scores

    The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 45 for total score. Change = observation mean minus baseline mean. Negative change indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52

  2. Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Sensory Scores

    The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 33 for sensory score. Change = observation mean minus baseline mean. Negative change indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52

  3. Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Affective Scores

    The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 12 for affective score. Change = observation mean minus baseline mean. Negative change indicated improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52

  4. Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score

    The mBPI-10 is a self administered questionnaire that assesses pain interference with functional activities over the past week. These items are measured on an 11 point scale, ranging from "does not interfere" (0) to "completely interferes" (10). A composite score, the Pain Interference Index, will be calculated by averaging the 10 items that comprise the scale. Change = observation mean at Week 52 minus baseline mean.

    Time frame: Baseline, Week 52

07

Results

Posted May 17, 2013

Participant flow

Japanese patients with central neuropathic pain after spinal cord injury who had completed the preceding A0081107 study (NCT00407745) were eligible for this study, and Japanese patients with pain after cerebral stroke or with multiple sclerosis pain were newly recruited.

Participant flow — Overall Study
MilestonePregabalin
Started103
Completed84
Not completed19
Withdrew: Adverse event16
Withdrew: Withdrawal by subject2
Withdrew: Lack of efficacy1

Outcome measures

PrimaryNumber of Participants With Peripheral Edema

Number of participants who had peripheral edema in lower extremities. Edema was categorized as follows: trace, pitting 1 (lower leg), 2 (lower leg to knee), and 3 (above knee and /or presacral edema).

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Peripheral Edema
ParticipantsPregabalin
Trace at Baseline (n=103)5
Pitting +1 at Baseline (n=103)9
Pitting +2 at Baseline (n=103)2
Pitting +3 at Baseline (n=103)0
Trace at Week 4 (n=101)8
Pitting +1 at Week 4 (n=101)8
Pitting +2 at Week 4 (n=101)4
Pitting +3 at Week 4 (n=101)1
Trace at Week 20 (n=93)8
Pitting +1 at Week 20 (n=93)3
Pitting +2 at Week 20 (n=93)7
Pitting +3 at Week 20 (n=93)0
Trace at Week 36 (n=90)14
Pitting +1 at Week 36 (n=90)7
Pitting +2 at Week 36 (n=90)3
Pitting +3 at Week 36 (n=90)0
Trace at Week 52/early termination (n=100)10
Pitting +1 at Week 52/early termination (n=100)7
Pitting +2 at Week 52/early termination (n=100)2
Pitting +3 at Week 52/early termination (n=100)0
Trace at Week 53/early termination (n=78)9
Pitting +1 at Week 53/early termination (n=78)5
Pitting +2 at Week 53/early termination (n=78)0
Pitting +3 at Week 53/early termination (n=78)0
PrimaryNumber of Participants With Facial/Periorbital Edema

Number of participants who had facial or periorbital edema.

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Facial/Periorbital Edema
ParticipantsPregabalin
Baseline (n=103)0
Week 4 (n=101)0
Week 20 (n=93)0
Week 36 (n=90)0
Week 52/early termination (n=100)1
Week 53/early termination (n=78)0
PrimaryNumber of Participants With Generalized or Abdominal Edema

Number of participants who had generalized or abdominal edema.

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Generalized or Abdominal Edema
ParticipantsPregabalin
Baseline (n=103)0
Week 4 (n=101)0
Week 20 (n=93)0
Week 36 (n=90)0
Week 52/early termination (n=100)1
Week 53/early termination (n=78)0
PrimaryNumber of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT)

DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT)
ParticipantsPregabalin
Mild at Baseline (n=103)2
Moderate at Baseline (n=103)3
Severe at Baseline (n=103)1
Mild at Week 4 (n=101)5
Moderate at Week 4 (n=101)1
Severe at Week 4 (n=101)0
Mild at Week 20 (n=93)3
Moderate at Week 20 (n=93)0
Severe at Week 20 (n=93)0
Mild at Week 36 (n=90)3
Moderate at Week 36 (n=90)0
Severe at Week 36 (n=90)0
Mild at Week 52/early termination (n=100)3
Moderate at Week 52/early termination (n=100)0
Severe at Week 52/early termination (n=100)1
Mild at Week 53/early termination (n=78)2
Moderate at Week 53/early termination (n=78)1
Severe at Week 53/early termination (n=78)0
PrimaryNumber of Participants With Localized Tenderness Related to Deep Vein Thrombosis (DVT)

DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Localized Tenderness Related to Deep Vein Thrombosis (DVT)
ParticipantsPregabalin
Mild at Baseline (n=103)0
Moderate at Baseline (n=103)0
Severe at Baseline (n=103)0
Mild at Week 4 (n=101)0
Moderate at Week 4 (n=101)0
Severe at Week 4 (n=101)0
Mild at Week 20 (n=93)0
Moderate at Week 20 (n=93)0
Severe at Week 20 (n=93)0
Mild at Week 36 (n=90)0
Moderate at Week 36 (n=90)0
Severe at Week 36 (n=90)0
Mild at Week 52/early termination (n=100)0
Moderate at Week 52/early termination (n=100)0
Severe at Week 52/early termination (n=100)0
Mild at Week 53/early termination (n=78)0
Moderate at Week 53/early termination (n=78)0
Severe at Week 53/early termination (n=78)0
PrimaryNumber of Participants With Swelling Related to Deep Vein Thrombosis (DVT)

DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Swelling Related to Deep Vein Thrombosis (DVT)
ParticipantsPregabalin
Mild at Baseline (n=103)4
Moderate at Baseline (n=103)2
Severe at Baseline (n=103)0
Mild at Week 4 (n=101)3
Moderate at Week 4 (n=101)2
Severe at Week 4 (n=101)0
Mild at Week 20 (n=93)3
Moderate at Week 20 (n=93)2
Severe at Week 20 (n=93)0
Mild at Week 36 (n=90)4
Moderate at Week 36 (n=90)1
Severe at Week 36 (n=90)0
Mild at Week 52/early termination (n=100)7
Moderate at Week 52/early termination (n=100)0
Severe at Week 52/early termination (n=100)0
Mild at Week 53/early termination (n=78)5
Moderate at Week 53/early termination (n=78)0
Severe at Week 53/early termination (n=78)0
PrimaryNumber of Participants With Pitting Edema Related to Deep Vein Thrombosis (DVT)

DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Pitting Edema Related to Deep Vein Thrombosis (DVT)
ParticipantsPregabalin
Mild at Baseline (n=103)6
Moderate at Baseline (n=103)1
Severe at Baseline (n=103)0
Mild at Week 4 (n=101)5
Moderate at Week 4 (n=101)2
Severe at Week 4 (n=101)0
Mild at Week 20 (n=93)4
Moderate at Week 20 (n=93)1
Severe at Week 20 (n=93)0
Mild at Week 36 (n=90)7
Moderate at Week 36 (n=90)0
Severe at Week 36 (n=90)0
Mild at Week 52/early termination (n=100)8
Moderate at Week 52/early termination (n=100)0
Severe at Week 52/early termination (n=100)0
Mild at Week 53/early termination (n=78)4
Moderate at Week 53/early termination (n=78)0
Severe at Week 53/early termination (n=78)0
PrimaryNumber of Participants With Collateral Superficial Veins (Non-varicose) Related to Deep Vein Thrombosis (DVT)

DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Collateral Superficial Veins (Non-varicose) Related to Deep Vein Thrombosis (DVT)
ParticipantsPregabalin
Mild at Baseline (n=103)0
Moderate at Baseline (n=103)0
Severe at Baseline (n=103)0
Mild at Week 4 (n=101)0
Moderate at Week 4 (n=101)0
Severe at Week 4 (n=101)0
Mild at Week 20 (n=93)0
Moderate at Week 20 (n=93)0
Severe at Week 20 (n=93)0
Mild at Week 36 (n=90)0
Moderate at Week 36 (n=90)0
Severe at Week 36 (n=90)0
Mild at Week 52/early termination (n=100)0
Moderate at Week 52/early termination (n=100)0
Severe at Week 52/early termination (n=100)0
Mild at Week 53/early termination (n=78)0
Moderate at Week 53/early termination (n=78)0
Severe at Week 53/early termination (n=78)0
PrimaryNumber of Participants With Skin Redness Related to Deep Vein Thrombosis (DVT)

DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.

Time frame:
Baseline, Weeks 4, 20, 36, 52, and 53
Reported as:
Number · Participants
Number of Participants With Skin Redness Related to Deep Vein Thrombosis (DVT)
ParticipantsPregabalin
Mild at Baseline (n=103)0
Moderate at Baseline (n=103)0
Severe at Baseline (n=103)0
Mild at Week 4 (n=101)0
Moderate at Week 4 (n=101)0
Severe at Week 4 (n=101)0
Mild at Week 20 (n=93)1
Moderate at Week 20 (n=93)0
Severe at Week 20 (n=93)0
Mild at Week 36 (n=90)0
Moderate at Week 36 (n=90)0
Severe at Week 36 (n=90)0
Mild at Week 52/early termination (n=100)0
Moderate at Week 52/early termination (n=100)0
Severe at Week 52/early termination (n=100)0
Mild at Week 53/early termination (n=78)0
Moderate at Week 53/early termination (n=78)0
Severe at Week 53/early termination (n=78)0
PrimaryNumber of Participants With Visual Field Deteriorated

Number of participants who had normal visual field at baseline and showed abnormal result after the study treatment, assessed by confrontational visual field test (neurological examination).

Time frame:
53 weeks
Reported as:
Number · Participants
Number of Participants With Visual Field Deteriorated
ParticipantsPregabalin
Right eye0
Left eye0
PrimaryNumber of Participants With Deterioration in Neurological Examination Findings

Worsening of the condition relative to baseline was reported as deteriorated. Assessment categories are as follows: normal or abnormal for Cranial Nerve Function, Mental State, and Coordination; normal, mild, moderate, or severe ataxia for Gait; none/absent, normal, or hyper-reflexic for Deep Tendon Reflexes; absent or present for Abnormal Reflexes; normal, mild, moderate, or severe weakness for Muscle Strength; slight, more marked, or considerable increase, or affected parts rigid in flexion or extension for Muscle Tone; absent or present for Sensory Function.

Time frame:
53 weeks
Reported as:
Number · Participants
Number of Participants With Deterioration in Neurological Examination Findings
ParticipantsPregabalin
Cranial Nerve Function0
Mental State0
Coordination: Right (R)- Finger to Nose0
Coordination: Left (L)- Finger to Nose2
Coordination: R- Finger Tapping1
Coordination: L- Finger Tapping0
Coordination: R- Rapid Alternating Hand Movement1
Coordination: L- Rapid Alternating Hand Movement2
Coordination: Romberg Test1
Gait1
Deep Tendon Reflexes: R- Brachioradialis1
Deep Tendon Reflexes: L- Brachioradialis1
Deep Tendon Reflexes: R-Patellar3
Deep Tendon Reflexes: L-Patellar3
Deep Tendon Reflexes: R- Achilles2
Deep Tendon Reflexes: L- Achilles3
Abnormal Reflexes1
Muscle Strength: R- Upper Limb1
Muscle Strength: L- Upper Limb2
Muscle Strength: R- Lower Limb1
Muscle Strength: L- Lower Limb2
Muscle Tone: R- Upper Limb1
Muscle Tone: L- Upper Limb1
Muscle Tone: R- Lower Limb5
Muscle Tone: L- Lower Limb5
Sensory Function: Anesthesia0
Sensory Function: Hypesthesia1
Sensory Function: Allodynia1
Sensory Function: Hyperalgesia2
PrimaryNumber of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS)

The Sheehan-STS is an 8-item prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Participants who reported a score of ≥1 (5-point scale ranging from 0: not at all to 4: extremely) for Item 2, 3, 4 or 5 of the Sheehan-STS prognostic scale is considered to have suicidal ideation as the scores are mapped to Category 4 (suicide ideation) of the Columbia Classification Algorithm of Suicide Assessment.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
Reported as:
Number · Participants
Number of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS)
ParticipantsPregabalin
Baseline (n=103)3
Week 2 (n=102)2
Week 4 (n=101)1
Week 8 (n=99)0
Week 12 (n=96)0
Week 20 (n=93)2
Week 28 (n=91)2
Week 36 (n=90)2
Week 44 (n=85)2
Week 52 (n=101)0
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Total Scores

The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 45 for total score. Change = observation mean minus baseline mean. Negative change indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
Reported as:
Mean · Score on a scale
Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Total Scores
Score on a scalePregabalin
Week 2 (n=103)-4.2 (-5.4 to -3.0)
Week 4 (n=102)-5.2 (-6.4 to -4.0)
Week 8 (n=99)-5.3 (-6.6 to -4.0)
Week 12 (n=98)-5.7 (-7.3 to -4.2)
Week 20 (n=95)-6.1 (-7.6 to -4.7)
Week 28 (n=92)-5.1 (-6.6 to -3.6)
Week 36 (n=91)-5.0 (-6.5 to -3.5)
Week 44 (n=87)-4.4 (-6.1 to -2.8)
Week 52 (n=85)-5.0 (-6.6 to -3.4)
Week 52 (LOCF, n=103)-4.6 (-6.2 to -3.0)
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Sensory Scores

The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 33 for sensory score. Change = observation mean minus baseline mean. Negative change indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
Reported as:
Mean · Score on a scale
Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Sensory Scores
Score on a scalePregabalin
Week 2 (n=103)-3.1 (-4.1 to -2.2)
Week 4 (n=102)-3.9 (-4.8 to -3.0)
Week 8 (n=99)-3.9 (-4.9 to -3.0)
Week 12 (n=98)-4.2 (-5.4 to -3.1)
Week 20 (n=95)-4.5 (-5.6 to -3.4)
Week 28 (n=92)-3.8 (-5.0 to -2.7)
Week 36 (n=91)-3.7 (-4.8 to -2.6)
Week 44 (n=87)-3.1 (-4.4 to -1.9)
Week 52 (n=85)-3.6 (-4.8 to -2.4)
Week 52 (LOCF, n=103)-3.6 (-4.8 to -2.4)
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Affective Scores

The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 12 for affective score. Change = observation mean minus baseline mean. Negative change indicated improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
Reported as:
Mean · Score on a scale
Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Affective Scores
Score on a scalePregabalin
Week 2 (n=103)-1.1 (-1.5 to -0.5)
Week 4 (n=102)-1.3 (-1.7 to -0.8)
Week 8 (n=99)-1.3 (-1.8 to -0.9)
Week 12 (n=98)-1.5 (-2.0 to -1.0)
Week 20 (n=95)-1.6 (-2.1 to -1.2)
Week 28 (n=92)-1.3 (-1.8 to -0.9)
Week 36 (n=91)-1.3 (-1.8 to -0.7)
Week 44 (n=87)-1.3 (-1.9 to -0.7)
Week 52 (n=85)-1.4 (-1.9 to -0.9)
Week 52 (LOCF, n=103)-1.0 (-1.5 to -0.5)
SecondaryChange From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score

The mBPI-10 is a self administered questionnaire that assesses pain interference with functional activities over the past week. These items are measured on an 11 point scale, ranging from "does not interfere" (0) to "completely interferes" (10). A composite score, the Pain Interference Index, will be calculated by averaging the 10 items that comprise the scale. Change = observation mean at Week 52 minus baseline mean.

Time frame:
Baseline, Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score
Score on a scalePregabalin
Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score-1.4 (-1.9 to -0.9)

Adverse events

Collected over 53 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—19/103 (18.4%)91/103 (88.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPregabalin
CellulitisInfections and infestations2/103
Cerebral infarctionNervous system disorders2/103
Arteriosclerosis coronary arteryCardiac disorders1/103
Anal fistulaGastrointestinal disorders1/103
Colonic polypGastrointestinal disorders1/103
Inguinal herniaGastrointestinal disorders1/103
MelaenaGastrointestinal disorders1/103
Tooth development disorderGastrointestinal disorders1/103
Cholangitis acuteHepatobiliary disorders1/103
Infected skin ulcerInfections and infestations1/103
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPregabalin
SomnolenceNervous system disorders53/103
Weight increasedInvestigations31/103
NasopharyngitisInfections and infestations26/103
DizzinessNervous system disorders24/103
Oedema peripheralGeneral disorders18/103
FallInjury, poisoning and procedural complications13/103
ConstipationGastrointestinal disorders8/103
ContusionInjury, poisoning and procedural complications8/103
Back painMusculoskeletal and connective tissue disorders8/103
RashSkin and subcutaneous tissue disorders8/103

Baseline characteristics

Age, Customized
Age, Customized(Participants)Pregabalin
>=18 and <45 years15
>= 45 and <65 years60
>=65 years28
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin
Female22
Male81
08

Study locations

26 sites
  • Chubu Rosai Hospital
    Nagoya, Aichi, Japan
  • Kimura Clinic
    Nagoya, Aichi, Japan
  • Nagoya Kyoritsu Clinic
    Nagoya, Aichi, Japan
  • Senboku Kumiai General Hospital
    Daisen, Akita, Japan
  • Go neurosurgical clinic
    Chikushi-gun, Fukuoka, Japan
  • Spinal Injuries Center
    Iizuka, Fukuoka, Japan
  • Brain Attack Center Ota Memorial Hospital
    Fukuyama, Hiroshima, Japan
  • Hokkaido Chuo Rosai Hospital Sekison Center
    Bibai, Hokkaido, Japan
  • Hakodate Central General Hospital
    Hakodate, Hokkaido, Japan
  • Kobe Tokushukai Hospital
    Kobe, Hyogo, Japan
  • Aida Kinen Rehabilitation Hospital
    Moriya, Ibaraki, Japan
  • General Hanamaki Hospital
    Hanamaki, Iwate, Japan
  • Uchida Rehabilitation Orthopedic Clinic
    Kawasaki, Kanagawa, Japan
  • Kumamoto Rehabilitation Hospital
    Kikuchi-gun, Kumamoto, Japan
  • Sendai Pain Clinic
    Sendai-city, Miyagi, Japan
  • Kohnan Hospital
    Sendai, Miyagi, Japan
  • National Hospital Organization Niigata National Hospital
    Kashiwazaki, Niigata, Japan
  • Nakamura Hospital
    Beppu, Oita, Japan
  • Kitasato University Kitasato Institute Medical Center Hospital
    Kitamoto, Saitama, Japan
  • Kamitsuga General Hospital
    Kanuma, Tochigi, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo, Japan
  • Jukoukai hospital
    Koto-ku, Tokyo, Japan
  • National Hospital Organization, Murayama Medical Center
    Musashimurayama-shi, Tokyo, Japan
  • Okitama Public General Hospital
    Higashiokitama-gun, Yamagata, Japan
  • Tokushima University Hospital
    Tokushima, Japan
  • National Hospital Organization Yamagata Hospital
    Yamagata, Japan
09

References and documents

Publications

  • Onouchi K, Koga H, Yokoyama K, Yoshiyama T. An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. J Pain Res. 2014 Jul 28;7:439-47. doi: 10.2147/JPR.S63028. eCollection 2014. PubMed 25114584 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2010
First posted
Sep 15, 2010
Start
Sep 2010
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results first posted
May 17, 2013
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01202227
Responsible party
Sponsor
First posted
Sep 15, 2010
Start date
Sep 2010
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
May 17, 2013
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion